The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Chlorphenamine Maleate Injection (2ml: 20mg and 1ml: 10mg), in which the 2ml: 20mg specification being the first and 1ml: 10mg specification being the second of respective approvals for the PRC entities. Chlorphenamine Maleate Injection is mainly used in the treatment of allergic rhinitis, and can also be used for colds or sinusitis, mucocutaneous allergy, and control of drug eruption and contact dermatitis.